Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Viscoli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Viscoli, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 41, 65-80, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

The evolution of the empirical management of fever and neutropenia in cancer patients

C Viscoli
University of Genoa, National Institute for Cancer Research, Italy. viscolic@igecuniv.cisi.unige.it

Infectious complications are an important cause of morbidity and mortality in cancer patients, especially those receiving chemotherapy. Furthermore, neutropenia, fever and infection limit the dose-intensity of antineoplastic chemotherapy in cancer patients. Fever without clinical signs of a localized infection is the commonest clinical presentation in neutropenic patients. Early empirical administration of broad-spectrum antibiotics at the onset of fever has become common practice, but the specific empirical regimen remains controversial. Guidance from therapeutic clinical trials is not straightforward, since it is difficult to compare trials, due to major differences and deficiencies in their design and analysis. Clinical trials fall into two categories: (i) explanatory trials which assess the hypothesis under ideal conditions, and (ii) pragmatic trials, which assess the regimen under the conditions of clinical practice. Methodological issues that are of crucial importance in the recognition of limits and value of the results of clinical trials in this field are discussed. The EORTC-IATCG has performed nine large therapeutic trials of empirical antibacterial and antifungal therapy in febrile, neutropenic patients with cancer. The results of trials, V, VIII, IX and XI are reviewed, and issues to be resolved in future trials are also considered.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
M. Miceli, R. Atoui, R. Walker, T. Mahfouz, N. Mirza, J. Diaz, G. Tricot, B. Barlogie, and E. Anaissie
Diagnosis of Deep Septic Thrombophlebitis in Cancer Patients by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Scanning: A Preliminary Report
J. Clin. Oncol., May 15, 2004; 22(10): 1949 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Fishman, B. R. Dey, and R. P. Hasserjian
Case 10-2004 - A 58-Year-Old Man with Acute Myeloid Leukemia and Fever after Chemotherapy
N. Engl. J. Med., March 25, 2004; 350(13): 1339 - 1347.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. E. Peacock Jr., D. A. Herrington, J. C. Wade, H. M. Lazarus, M. D. Reed, J. W. Sinclair, D. C. Haverstock, S. F. Kowalsky, D. D. Hurd, D. A. Cushing, et al.
Ciprofloxacin plus Piperacillin Compared with Tobramycin plus Piperacillin as Empirical Therapy in Febrile Neutropenic Patients: A Randomized, Double-Blind Trial
Ann Intern Med, July 16, 2002; 137(2): 77 - 87.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.